Inflammatory Bowel Diseases(IBD)is a class of genetically related diseases caused by multiple genes and environmental factors that accelerate the disturbance of the immune-gut-microbiome axis.Lesions often involve multiple organs and systems.Biological agents are an important means of treating IBD and its extraintestinal manifestations.Current studies suggest that biologics can bring benefits to patients,but paradoxical skin lesions,joint lesions,and ocular lesions appear during the treatment.Diseases,pulmonary lesions and other manifestations or lesions are easily ignored in clinical practice,thereby delaying the patient's condition and affecting the patient's quality of life.Therefore,by summarizing the clinical characteristics and diagnosis and treatment experience of contradictory extraintestinal manifestations in the current application of biological agents,this review aims to improve the understanding of clinicians,identify this clinical manifestation early,and avoid delaying the patient's condition.

Inflammatory bowel disease (IBD) has recurrent and protracted course with unknown etiology and it can affect multiple organs and systems. At present, IBD patients tends to be younger, and the recurrent disease affects work, even resulting in unemployment, and consumes a lot of social and medical resources. Having been used for the treatment of IBD for more than 20 years, biologics increase the selectivity of treatment, but at the same time, current research has found that the use of biologics is one of the main factors increasing the economic burden of IBD. Compared with biologics, biosimilars have significant advantages in optimizing cost-benefit and have good application prospects. By summarizing the current research status of IBD health economics at home and abroad, this review aims to provide an economic basis for strengthening disease management and improving the quality of life of patients.

Inflammatory bowel disease (IBD) has recurrent and protracted course with unknown etiology and it can affect multiple organs and systems. At present, IBD patients tends to be younger, and the recurrent disease affects work, even resulting in unemployment, and consumes a lot of social and medical resources. Having been used for the treatment of IBD for more than 20 years, biologics increase the selectivity of treatment, but at the same time, current research has found that the use of biologics is one of the main factors increasing the economic burden of IBD. Compared with biologics, biosimilars have significant advantages in optimizing cost-benefit and have good application prospects. By summarizing the current research status of IBD health economics at home and abroad, this review aims to provide an economic basis for strengthening disease management and improving the quality of life of patients.

Inflammatory bowel disease (IBD) is an idiopathic inflammatory disease of gastrointestinal tract, which mainly includes Crohn’s disease (CD) and ulcerative colitis (UC). The existence of chronic diseases is an important influencing factor of sleep quality, and sleep quality is a key index to evaluate the quality of life. Sleep disorder can lead to fatigue, anxiety and stress. The incidence of sleep disorder in patients with active IBD is higher than that in remission IBD. When patients with IBD get worse, the sleep disorder is more serious, while sleep disorder can aggravate intestinal inflammation and injury recovery. This article summarized the research on the correlation between sleep disorder and IBD, and clarified their two - way interaction, so as to provide reference for the clinical management and treatment of sleep disorder associated with IBD.